ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.673,16
-0,28%
S&P 500
5.321,41
0,25%
Dow Jones
39.872,99
0,17%
Euro vs US Dollar
1,08502
-0,04%
Bitcoin
70.114,05
-0,02%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Eterna Therapeutics Inc (ERNA)

  7. Eterna Therapeutics Inc (ERNA) News

ERNA

Eterna Therapeutics (ERNA)

Eterna Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ERNA
DatumZeitQuelleÜberschriftSymbolFirma
14/05/202423h14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ERNAEterna Therapeutics Inc
10/05/202414h00GlobeNewswire Inc.Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs iNASDAQ:ERNAEterna Therapeutics Inc
08/05/202415h31GlobeNewswire Inc.Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory BoardNASDAQ:ERNAEterna Therapeutics Inc
07/05/202414h00GlobeNewswire Inc.Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M LocusNASDAQ:ERNAEterna Therapeutics Inc
07/05/202414h00GlobeNewswire Inc.Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs iNASDAQ:ERNAEterna Therapeutics Inc
20/02/202414h30GlobeNewswire Inc.Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of DirectorsNASDAQ:ERNAEterna Therapeutics Inc
16/02/202423h30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
16/02/202413h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ERNAEterna Therapeutics Inc
31/01/202413h05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ERNAEterna Therapeutics Inc
24/01/202422h15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ERNAEterna Therapeutics Inc
23/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ERNAEterna Therapeutics Inc
19/01/202422h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ERNAEterna Therapeutics Inc
19/01/202416h31Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ERNAEterna Therapeutics Inc
16/01/202422h16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ERNAEterna Therapeutics Inc
12/01/202422h49Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ERNAEterna Therapeutics Inc
03/01/202423h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
03/01/202423h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
03/01/202423h01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
03/01/202422h15GlobeNewswire Inc.Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)NASDAQ:ERNAEterna Therapeutics Inc
22/12/202318h05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ERNAEterna Therapeutics Inc
20/12/202322h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ERNAEterna Therapeutics Inc
20/12/202322h15GlobeNewswire Inc.Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive OfficerNASDAQ:ERNAEterna Therapeutics Inc
20/12/202321h24Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ERNAEterna Therapeutics Inc
20/12/202316h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
19/12/202303h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
15/12/202300h56GlobeNewswire Inc.Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant FinancingNASDAQ:ERNAEterna Therapeutics Inc
14/12/202322h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ERNAEterna Therapeutics Inc
16/11/202322h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ERNAEterna Therapeutics Inc
13/11/202323h30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
13/11/202314h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ERNAEterna Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ERNA

Kürzlich von Ihnen besucht

COIN
PHMGBP
USOTC
PKTEF
Parkit Enterprise (PK)
AMEX
LMZ
EU
1246T
1246T
NASDAQ
HRMY
Harmony Biosciences
COIN
SPNGBP
BIT
P77138
BNP Paribas
TSXV
OG.H
Oragin Foods
USOTC
BIOVF
Swedish Orphan Biovitrum... (PK)
EU
0045N
Natixis Sa null
TSXV
SPW
NASDAQ
BTRSW
BTRS
NASDAQ
CSSE
Chicken Soup for the Sou...
COIN
MTBUSD
MobileTokenBank
EU
5006T
5006T
NASDAQ
TAPR
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten